AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06500715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be administered bilaterally on points PC6, LI 4, CV6, SP6, SP10 and ST36 on the first day of each cycle (d1), prior to administration of chemotherapy; and on d8, each session lasting between 30 to 45 minutes. Patients will continue from d1 to d8 with press-tack acupuncture needles on points PC 6, LI4, SP 6 and ST 36. On d8, patients will again undergo acupuncture, and continue with self-acupressure on the same points as the press-tack needles, until the next chemotherapy cycle.
Study NCT04105660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training for EEG monitoring
Description: Training for reading EEG curves during anaesthesia
Study NCT04105660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard monitoring
Description: Standard monitoring including clinical parameters and BIS index
Study NCT04105660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard monitoring
Description: Standard monitoring including clinical parameters and BIS index
Study NCT05016050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPDT-DA-013
Description: Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).
Study NCT05796973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided physical exercise
Description: Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions.
Study NCT05796973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. In addition to the exercise program they will be given atorvastatin 40 mg QD medication.
Study NCT05796973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Independent exercise
Description: The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own.
Study NCT05768464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study NCT05768464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg orraly twice daily
Study NCT05644483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)
Study NCT05644483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol: target controlled infusion: 2-3mcg/mL
Study NCT06473818 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive monitoring
Description: Non-invasive cardiac output monitoring
Study NCT06473818 — intervention group
Intervention type: DEVICE
Intervention: Invasive monitoring
Description: Invasive cardiac output monitoring
Study NCT04373070 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: CAir
Description: The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 \[2017\], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.
Study NCT04373070 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CAir
Description: The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 \[2017\], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.
Study NCT05551221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin Capsules
Description: Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
Study NCT05551221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningmitai capsule
Description: Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
Study NCT05551221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
Study NCT04913675 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sotrovimab
Description: Sotrovimab 500 mg given by intravenous infusion over 15 min
Study NCT04913675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: Sotrovimab 500 mg given by intramuscular injection
Study NCT04913675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: Sotrovimab 250 mg given by intramuscular injection
Study NCT04913675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: Sotrovimab 2000 mg given by intravenous infusion over 60 min
Study NCT04913675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Sotrovimab 2000 mg given by intravenous infusion over 30 min
Study NCT04913675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Sotrovimab 2000 mg given by intravenous infusion over 15 min
Study NCT04913675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Sotrovimab up to 3000 mg given by intravenous infusion over 90 min
Study NCT04995107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro Press needle
Description: Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed).
Study NCT06093659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product A)
Description: Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
Study NCT05277012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant capsule and tablet formulations
Study NCT06093659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product B)
Description: Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
Study NCT04937400 — intervention group
Intervention type: OTHER
Intervention: Daily screening for delirium
Description: Each child will be screened twice daily for delirium throughout the transplant hospitalization
Study NCT06093659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with nicotine-infused heated herbal sticks (Product C)
Description: Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
Study NCT06093659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with nicotine-infused heated herbal sticks (Product D)
Description: Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
Study NCT06093659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Cigarette (Product E)
Description: Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
Study NCT05849974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural and fonctional phynotyping
Description: The additioan acts in this research are:~Fonctionnal phenotyping:Retinal sensitivity and fixation stability assessment using microperimetry, assessment of long-term fixation stability Structural Phenotyping: Anterior segment examination with OCT anterior Blood sample collection
Study NCT04040673 — intervention group
Intervention type: PROCEDURE
Intervention: thyroid lobectomy
Description: routine surgical removal of thyroid for biopsy
Study NCT04040673 — intervention group
Intervention type: DEVICE
Intervention: Raman spectroscopy probe measurement
Description: The measurement of Raman spectra from the excised tissue
Study NCT06510426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif 44 MCG Per 0.5 ML Prefilled Syringe
Description: Rebif 44mcg per 0.5ml administered subcutaneously
Study NCT05690191 — intervention group
Intervention type: DRUG
Intervention: Chidamide
Description: Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
Study NCT05690191 — intervention group
Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
Study NCT05690191 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
Study NCT06510426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5mL of saline administered subcutaneously
Study NCT06501222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study NCT06501222 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study NCT06102213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)
Description: PBCLN-010: Human Milk Oligosaccharides (HMO). PBCLN-014: B. infantis.
Study NCT05236348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia.product-us
Description: The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.
Study NCT06559813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-by-step: A cognitive behavioral parent program with role-plays in virtual reality
Description: A parent training program based on social learning theory and cognitive behavioral therapy (CBT), incorporating virtual reality for training in brief role plays. The program includes similar strategies as other common CBT-parent training programs for parents of children with behavior problems, with the difference that virtual reality is used as an additional way to practice skills.
Study NCT04836494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-671
Description: BBP-671, oral suspension
Study NCT04836494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BBP-671
Study NCT04836494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-671
Description: BBP-671, tablet
Study NCT06445049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brief test
Description: The intervention is a simple brief test as follows: With the ventilator set with the patient clinical settings, it will be performed an up to 30sec-long or two inspiratory effort and-expiratory occlusion maneuver on the ventilator and/or switch the patient to pressure support for up to 30sec-long to assess the presence of intrinsic respiratory rate.~If an intrinsic respiratory rate ≥8 breaths per minute is present and P/F ratio is ≥150 it will be performed a 5-minute test in pressure support ventilation with the pressure support level to match the clinical setting of the patient. If the patient tolerates well 5 minutes in pressure support (see criteria below) the clinical team will be informed:~- It will be indicated that the patient tolerated 5 min of PSV and suggest to the clinicians and physician in charge to transition the patient to pressure support ventilation plus suggest reducing sedation.
Study NCT05003232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) and ICM+
Description: The intervention group will be given continuous NIRS and invasive blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP. Then the goal of blood pressure (within 5 mmHg of CPPopt) will be maintained as the target of blood pressure management for the intervention group during ICU stay.
Study NCT05301608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 10 mg of psilocybin.
Study NCT05301608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 10 mg of psilocybin.
Study NCT05301608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
Study NCT05301608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
Study NCT05192720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andosan
Description: See also detailed study design, Mushroom juice based on Agaricus Blazei and two other types of mushroom.
Study NCT05192720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: drinking water with food colour
Study NCT05095181 — intervention group
Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample
Study NCT06130215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple meal management
Description: * Regular meal: Total Carbs per Day x 0.6 / 3~* Large meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5
Study NCT05749185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency high voltage
Description: nvolved a high voltage PRF technique, where the voltage started at 65 V and could be adjusted up to 80 V based on patient tolerance. Both protocols involved two cycles of PRF application, with each cycle lasting 240 seconds and comprising alternating periods of current application and deactivation. The pulse rate frequency was set at 2 Hertz (Hz), resulting in two active phases/second (20 milliseconds (ms) of current application followed by 480 ms without stimulation)
Study NCT05749185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard RF
Description: A standard voltage PRF technique, administering PRF at a fixed voltage of 45 volts (V)
Study NCT04914039 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Combination Product
Description: Cases of brain death confirmed by the classic brain death confirmation test
Study NCT04914039 — intervention group
Intervention type: OTHER
Intervention: NO CTA examination
Description: NO CTA examination
Study NCT04746521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multitest 6 color TBNK and BD Lyotubes
Description: The Multitest 6 color TBNK allows us to count the population-specific B, T, NK cells
Study NCT04746521 — intervention group
Intervention type: BIOLOGICAL
Intervention: genomicDNA extraction
Description: Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood \& Tissue kit (QIAGEN), according to manufacturer protocols
Study NCT06130215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Precise meal management
Description: precise carbohydrate counting for each meal
Study NCT05782088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Piezocision
Description: Piezocision will be performed only once before the onset of canine retraction (T0) on one side of the maxillary arch that will be randomly chosen.
Study NCT05782088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeated Piezocision
Description: Piezocision will be repeated three times, on a monthly basis (T0, T1, and T2), over the 12-week study period.
Study NCT06150963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Study participants assigned to the VR intervention group were fitted with an HP Reverb G2 Head Mounted Display (HMD) and a wireless mouse prior to preparation for procedure. One virtual environment was utilized, integrating passive and active participant input via gyroscopic motion detection and computer mouse input.
Study NCT06150963 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Procedure Thyroid Biopsy
Description: In this procedure the patient lies down on a bed with their neck tilted back to reveal the thyroid gland. The doctor cleans the skin over the nodule and numbs it with a local anesthetic. The doctor will then use an ultrasound device to visualize the nodule and guide a needle to obtain cells through the syringe. This process may be repeated several times to retrieve adequate tissue for analysis.
Study NCT06150963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Procedure Thyroid Biopsy
Description: In this procedure the patient lies down on a bed with their neck tilted back to reveal the thyroid gland. The doctor cleans the skin over the nodule and numbs it with a local anesthetic. The doctor will then use an ultrasound device to visualize the nodule and guide a needle to obtain cells through the syringe. This process may be repeated several times to retrieve adequate tissue for analysis.
Study NCT06150963 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Procedure PICC Placement
Description: In this procedure the patient lies down on a bed and has their arm cleaned and then numbed with a local anesthetic. The doctor then uses an ultrasound to locate a suitable vein in the arm, typically above the elbow. The physician then makes a small incision in the skin and inserts a needle into the vein, followed by guidance of the Peripherally Inserted Central Catheter (PICC) through the needle until it reaches a large vein near the heart. The final position is confirmed by X-ray and the PICC line is secured at the site of insertion.